At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Registry of Asthma Patients Initiating DUPIXENT® (RAPID)
In Brief
An observational study evaluating DUPIXENT® for Asthma. Completed, enrolled 718 participants across 128 sites in 10 countries.
Signals
Detailed Summary
The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of: * Patient demographics (eg, gender, age, and race) * Patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height) The secondary objectives of the study are: * To characterize real-world use patterns of DUPIXENT® for asthma * To assess the long-term effectiveness of DUPIXENT® in asthma patients in a real-world setting * To assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT® * To collect long-term safety data on study participants in the real-world setting
Study Details
Timeline
Interventions
There is no investigational product provided by the study sponsor and no therapeutic intervention regulated by this protocol. As a condition for eligibility, patients are required to initiate DUPIXENT® for asthma, according to the country-specific prescribing information, prescribed by their physician as part of their normal care (ie, not for the purpose of enrolling in the registry). Once patients enter the study, there are no protocol requirements regarding DUPIXENT® or any other treatments.